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Abstract
Objective. To evaluate the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-
MDQ), the revised Bristol Rheumatoid Arthritis Numerical Rating Scales (BRAF-NRS V2) and the
Rheumatoid Arthritis Impact of Disease (RAID) scale in six countries.
Methods. We surveyed RA patients in France, Germany, The Netherlands, Spain, Sweden and the UK,
including the HAQ, 36-item Short Form Health Survey (SF-36) and potential revisions of the BRAF-NRS
coping and Spanish RAID coping items. Factor structure and internal consistency were examined by
factor analysis and Cronbach’s a and construct validity by Spearman’s correlation.
Results. A total of 1276 patients participated (76% female, 25% with a disease duration <5 years, median
HAQ 1.0). The original BRAF-MDQ four-factor structure and RAID single-factor structure were confirmed in
every country with 566% of variation in items explained by each factor and all item factor loadings of
0.710.98. Internal consistency for the BRAF-MDQ total and subscales was a Cronbach’s a of 0.750.96
and for RAID, 0.930.96. Fatigue construct validity was shown for the BRAF-MDQ and BRAF-NRS severity
and effect scales, correlated internally with SF-36 vitality and with RAID fatigue (r= 0.630.93). Broader
construct validity for the BRAFs and RAID was shown by correlation with each other, HAQ and SF-36
domains (r= 0.460.82), with similar patterns in individual countries. The revised BRAF-NRS V2 Coping
item had stronger validity than the original in all analyses. The revised Spanish RAID coping item per-
formed as well as the original.
Conclusion. Across six European countries, the BRAF-MDQ identifies the same four aspects of fatigue,
and along with the RAID, shows strong factor structure and internal consistency and moderategood
construct validity. The revised BRAF-NRS V2 shows improved construct validity and replaces the original.
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Rheumatology key messages
. Rheumatoid arthritis fatigue and impact measures demonstrate similar structure and validity across six European
countries.
. Fatigue comprises similar multidimensional components across western cultures, challenging the value of global
fatigue measures.
. The revised Bristol RA Fatigue Numerical Rating Scales demonstrates stronger validation for coping with fatigue.
Introduction
Pharmacological and non-pharmacological interventions aim
to reduce the impact of RA, such as pain, disability, fatigue
and distress [13]. Such outcomes are evaluated using pa-
tient-reported outcome measures (PROMs) such as the
Bristol Rheumatoid Arthritis Fatigue Multidimensional
Questionnaire (BRAF-MDQ) and Bristol Rheumatoid Arthritis
Numerical Rating Scales (BRAF-NRS, a trio of simple NRSs
for fatigue severity, effect and coping) and the RA Impact
of Disease (RAID) scale, developed to measure broader im-
pacts of RA not captured by existing single item PROMs for
pain, disability and function [49]. As studies are increasingly
conducted internationally, the RAID was developed simultan-
eously in 12 European countries. After development in the
UK, the BRAFs were translated into 37 languages using
formal protocols. BRAF translations were conducted by a
medical PROM translation company, supported by the
BRAF authors and based on internationally published guide-
lines [10]. Initial RAID translations were undertaken by
rheumatology clinicians using a similar but slightly simpler
protocol, although later translations were professionally per-
formed. In a systematic review identifying >30 published
guidelines on the translation and cultural adaptation of
PROMs [11], and in cognitive interviewing studies [12],
these two methods appeared to be equally robust.
Whether the questionnaires retain equivalence in their full
internal structure and appropriate construct validity is the
subject of this report.
While terminologies differ, classic texts and authoritative
review articles highlight the requirement for ensuring that
adaptations have conceptual equivalence (e.g. meaning of
distress), item equivalence (e.g. relevance of gardening
in a high-rise city), operational equivalence (e.g. scoring
systems such as an NRS) and semantic equivalence
(e.g. terms for coping) across cultures before a PROM is
ready for testing of psychometric (measurement) equiva-
lence [13, 14]. Cognitive interviewing is a systematic
methodology for this preparatory work [1517], and a
recent study demonstrated item and semantic equivalence
for the BRAF-MDQ, BRAF-NRS and RAID across six
European countries [12]. The cognitive interviews poten-
tially identified an operational and a conceptual weakness
in two PROM items relating to coping [12]. For the BRAF-
NRS coping item, many Dutch participants struggled with
the operational issue of low scores reflecting poor coping
(0, not at all well10, very well) while for the other tradition-
ally worded BRAF-NRS (severity and effect), high scores
reflect a worse situation. This direction of layout had been
requested by patients during BRAF development, as they
felt a high score should reflect strong coping skills [4]. The
phraseology of the RAID item on coping confused many
Spanish participants [12], and this appeared to relate to a
conceptual issue about capturing the fundamental mean-
ing of coping. Therefore the present study included
different versions of these two items so their performance
could be compared.
The cognitive interviewing study prepared the way for
the current study, a psychometric evaluation of validity
across the six countries. Psychometric equivalence in-
cludes many aspects of measurement performance,
including criterion validity (accuracy), construct validity
(association with variables that make theoretical sense),
a stable structure (e.g. factors or subscales), internal con-
sistency (items capturing cohesive concepts), sensitivity
to change and testretest reliability (stability) [18].
Construct validity, a consistent structure of four distinct
subscales that reflect different elements of fatigue, and
internal consistency have been demonstrated for the
BRAF-MDQ in the UK [5] but have not yet been tested
in other European countries. If the translations capture
concepts that mirror those demonstrated in the UK, then
the items within each factor should also represent a single
dimension in each country that can be tested by an ap-
propriate factor analysis (see Methods section). If these
factors are inconsistent across countries, this might indi-
cate important cultural differences in fatigue perception.
Further, construct validity of the RAID, a stable structure
and internal consistency have been demonstrated in many
countries [8] but not yet evaluated in Sweden, where the
Swedish RAID has been newly translated.
While desirable, it would be impractical to examine the
construct of RA fatigue in all 37 BRAF translations simul-
taneously. However, examining the performance in several
countries could provide important proof-of-concept infor-
mation on whether the fatigue components appear
common. Since the impact of RA is a useful construct
for comparison with fatigue, and since the new Swedish
RAID has not yet been validated, collaboration with the
RAID developers in a combined study is pragmatic.
The aims of this study were therefore to evaluate the
factor structure, internal consistency and construct val-
idity of the BRAF-MDQ, BRAF-NRS and RAID across six
European countries as exemplars and to test the construct
validity of a possible revision of the BRAF-NRS coping item
and of the Spanish RAID coping item, which arose from a
previous cognitive interviewing study in these countries [12].
Methods
Study design
A cross-sectional study was performed across France,
Germany, The Netherlands, Spain, Sweden and the UK
during 201314.
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Patients
Consecutive patients attending hospital rheumatology
outpatient departments were invited to participate or
were invited by post using departmental databases
(Spain included a private practice). Patients had to be
518 years of age with a diagnosis of RA [19], and were
excluded only if they lacked the capacity to consent.
Data collection
Demographic data comprised gender, age (<40, 4059,
560 years), disease duration (<5 years,55 years), medica-
tion and patient global NRS (Considering all the ways your
arthritis affects you, please mark below how well you are
doing: 0, very well10, very poor) [20]. Patients completed
the relevant language translations of the BRAF-MDQ,
BRAF-NRS, revised BRAF-NRS V2 and RAID (supplemen-
tary data, section BRAF-MDQ, Revised BRAF-NRS V2 and
the RAID: The Scales, available at Rheumatology Online),
with Spanish patients also completing a revised Spanish
RAID coping item. The BRAF-MDQ comprises 20 items
(yielding a total score of 070) and four subscales of phys-
ical fatigue (022), living with fatigue (021), cognitive fatigue
(015) and emotional fatigue (012), with high scores repre-
senting worse fatigue [4, 5]. The BRAF-NRS comprises
three items measuring fatigue severity, effect and coping.
The BRAF-NRS for severity and effect have high scores re-
flecting worse situations (010). However, as requested by
patients during development, the BRAF-NRS coping scale
is scored with 10 reflecting strong coping skills (Please circle
the number which shows how well you have coped with
fatigue over the past 7 days: 0, not at all well10, very
well) [4]. Based on the cognitive interviewing study [12], a
potential revision of the BRAF-NRS coping item was de-
veloped with 10 as worse coping (0, very well10, not at
all well) and tested here as an additional item. The RAID
contains seven NRSs to capture the impact of RA on
pain, functional disability, fatigue, sleep, physical and emo-
tional well-being and coping [79]. Each NRS score is
weighted for importance using standardized weightings
derived from a patient survey, then all seven are summed
to yield a single, composite score from 0 to 10, where a high
score indicates worse health [79]. A potential revised RAID
coping item for Spain was included based on the cognitive
interviewing results, using the phrase ‘arreglado (ha llevado,
afrontado, se ha apan˜ado)’ [sort out (deal with, cope with,
manage)] [12]. Comparator questionnaires for validation of
the BRAFs and RAID were the HAQ and 36-item Short Form
Health Survey (SF-36). The HAQ assesses disability using
20 items, yielding a total score of 03, where 3 represents
worse disability [21]. The SF-36 comprises eight health do-
mains (physical function, physical role, emotional role, social
function, pain, mental health, vitality and general health)
yielding scores of 0100, where 0 represents worse health
[22]. To prevent any order effects, two versions of the ques-
tionnaire packs were created with the PROMs in different
orders. Furthermore, the two potential revised coping items
were separated from their original versions by other ques-
tionnaires and also presented in two different orders. Paper
questionnaire packs were distributed in no particular order
and patients completed them either in the clinic or at home.
BRAFs are freely available from http://www1.uwe.ac.uk/hls/
research/healthandclinicalresearch/researchareas/longter
mconditions/fatiguescales.aspx and the RAID from http://
oml.eular.org/.
Ethics
Research ethics committee approval was obtained in the
UK (London, City Road and Hampstead Ethics Committee,
12/LO/1198). The principal investigator in each country
then obtained local approvals as required. Patients pro-
vided written informed consent. Anonymous question-
naires were returned to Bristol, UK for data entry and
analysis.
Analysis
Missing data from individual PROMs were dealt with ac-
cording to individual PROM scoring guidelines. A statis-
tical analysis plan was agreed to in advance and analysis
was performed on the total dataset and by individual
country. Factor structure was examined for the BRAF-
MDQ by testing whether the items in each of the original
factors also represent a single dimension in the new data
collected for the present study. Using the items within
each of the original factors, a separate factor analysis
was conducted for each country to identify the number
of factors with eigenvalues >1. If only a single factor
emerged from each analysis, this confirmed agreement
with the original UK factor. In addition, the robustness of
these results was investigated by repeated factor ana-
lyses on random samples of 50% of patients (bootstrap-
ping, 20 samples  6 countries  4 factors = 480 tests).
A similar factor analysis was also performed on the RAID
to check for the original unidimensional structure across
countries. The internal consistency of the BRAF-MDQ and
RAID was tested using Cronbach’s a. Construct validity
for the BRAF-MDQ and BRAF-NRS severity and effect
was evaluated using Spearman’s correlation to examine
the pattern of correlations between the BRAF-MDQ sub-
scales, with the RAID fatigue item and with the SF-36 vi-
tality subscale. Broader construct validity of the BRAFs
and RAID was evaluated through Spearman’s correlation
with the remaining eight SF-36 health subscales and the
HAQ. The performance of potential revisions to the coping
items was evaluated by comparing the construct validity
of the revisions with the originals. Construct validity for the
revised BRAF-NRS V2 (coping) was first evaluated by cor-
relation with the original item, all other fatigue items and
the RAID coping item and then with the remaining SF-36
health subscales, RAID and HAQ, as was the revised
Spanish RAID coping item (Spearman’s correlations).
Findings similar to the original validation during develop-
ment [5, 8] would indicate acceptability, with a high
proportion of variance accounted for and meeting recom-
mended criteria of Cronbach’s a 50.7 and correlation
50.45 [23]. Factor analysis requires 410 respondents
per item; to accommodate the 20-item BRAF-MDQ, a
sample size of 100200 patients per country was sought
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[24]. Analysis was performed using SPSS version 21.0
(IBM, Armonk, NY, USA).
Results
A total of 1276 patients participated, achieving 5150 pa-
tients per country. There was a preponderance of female
participants, people >60 years of age and those with longer
disease duration, reflecting the wider RA population (Table
1). Biologic agents were being used by 37% of patients (UK
16% to Sweden 65%). The mean fatigue and impact scores
were moderate with a good range of responses, as indi-
cated by the wide standard deviations. The UK participants
had slightly poorer health status than other countries for
most indices. The overall proportion of missing data was
small at 2.7% (345 of 12 760 items; supplementary Table
S1, available at Rheumatology Online).
Factor structure
The factor analysis showed that the original four factors of
the BRAF-MDQ (physical, living, cognitive and emotional
fatigue) and the single RAID factor were upheld in the total
patient sample taken together and in each of the individual
countries. All items loaded strongly on their respective
factors (0.710.98; supplementary Table S2, available at
Rheumatology Online), explaining a high proportion of the
variance for the items in each factor (all 566%; Table 2).
Repeated analyses using random 50% samples of the
data demonstrated the robustness of the factor structure,
with 476/480 tests (99%) showing the same (four factor)
structure for the BRAF-MDQ and indicating that the struc-
ture was not dependant on including particular respond-
ents. In one of each of the 20 tests for France, Germany,
Spain and Sweden, the living factor was split into two
factors (daily life, social life).
Internal consistency
Cronbach’s a demonstrated internal consistency by coun-
try and for the total sample for the BRAF-MDQ total score,
the BRAF-MDQ subscales and the RAID (Table 3). The
internal consistency for the BRAF-MDQ physical subscale
was slightly lower than other subscales, but still satisfac-
tory at 50.75 in all countries.
Construct validity with fatigue items
Construct validity for the BRAF-MDQ and BRAF-NRS for
severity and effect was demonstrated by moderate to
strong correlation between the fatigue subscales and
NRS, and with the SF-36 vitality subscale and the RAID
fatigue item (Table 4; r= 0.630.93). This pattern was simi-
lar in all individual countries (supplementary Table S3,
available at Rheumatology Online).
Construct validity with related broader concepts
The BRAF-MDQ, BRAF-NRS severity, BRAF-NRS effect
and RAID showed good construct validity through mod-
erate to strong correlations with each other, disability
(HAQ) and the SF-36 health domains (Table 5;
r= 0.460.82). This pattern of correlations was replicated
in individual countries (supplementary Table S4, available
at Rheumatology Online).
Validation of potential revised coping items
The revised BRAF-NRS V2 coping item showed stronger
construct validity than the original NRS coping item overall
(Table 6; revised r= 0.150.74, original r= 0.090.48) and in
each country (supplementary Table S5, available at
Rheumatology Online). An unexpected finding during
validity testing of the BRAF-NRS coping item was that
for Spain (n= 157), but none of the other countries
(n= 1119), the construct correlations for the original
BRAF-NRS coping version were always in the inappropri-
ate direction (except for correlation with BRAF-MDQ total
score). These inappropriate correlational directions were
rectified with the revised BRAF-NRS V2 coping item
(Table 6). Based on these results, the BRAF-NRS V2 con-
taining the original severity and effect items but the revised
coping item now replaces the original BRAF-NRS. Since
the original BRAF-NRS coping item correlates only weakly
with the revised BRAF-NRS V2 coping item (r = 0.348 for
a five country sample, 0.082 for Spain), patient ratings
already obtained using the original version cannot simply
be reverse scored to make them comparable to V2.
The Spanish alternative wording for the RAID coping
item correlated well with the original item (r= 0.89,
n= 157) and demonstrated a similar pattern of construct
validity with the eight SF-36 health subscales (original
r= 0.510.66, revised r= 0.390.74; supplementary Table
S6, available at Rheumatology Online). Therefore the
original Spanish wording for this item was retained.
Discussion
This study tested the performance of the BRAF-MDQ, the
BRAF-NRS and the RAID in six European countries for
the first time and found that they retained their internal
structure and satisfactory construct validity in all coun-
tries. The study also demonstrated the improved perform-
ance of the revised BRAF-NRS V2 coping item compared
with the original, which it now replaces, and confirmed
that there was no need to replace the original RAID
coping item for Spain, which performed satisfactorily.
These novel data suggest these PROMs can be used
with confidence in a range of countries, facilitating
international comparison.
Factor analysis demonstrated that the four original fa-
tigue subscales developed in the BRAF-MDQ (physical
fatigue, living with fatigue, cognitive fatigue and emotional
fatigue) are confirmed in a fresh UK population and are
also confirmed in five other European countries. This sug-
gests fatigue has a similar construct from the patient’s
perspective across these western cultures, although this
has yet to be tested in other cultures [25]. Such general-
izability was hypothesized from cognitive interviewing
across these European countries [12] and strengthens
the argument that fatigue is not a unidimensional concept
but has aspects that may vary between patients [4, 5],
potentially questioning the value of the BRAF-MDQ total
score and global fatigue questions or PROMs.
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For example, while the Functional Assessment of Chronic
Illness TherapyFatigue has been used in RA clinical trials,
it was not developed for or with RA patients and provides
only a unidimensional global fatigue score, as does the
Patient-Reported Outcomes Measurement Information
System [26, 27]. The three unidimensional BRAF-NRS
items nonetheless provide a rapid assessment of fatigue
severity, effect and coping where questionnaire burden
would otherwise be high and fatigue is not the primary
aim of treatment or research.
The internal consistency of the BRAF-MDQ, BRAF-NRS
and RAID was further supported by construct validity in
six European countries, providing novel data for the BRAF
scales and the new Swedish RAID. Construct validity for
the BRAFs was demonstrated against the SF-36 vitality
domain and the RAID fatigue question (both fatigue sever-
ity items). These had strong correlations with the BRAF-
MDQ total, physical and living with fatigue items and with
the BRAF-NRS severity and effect items and more mod-
erate correlations with the BRAF-MDQ emotional and
cognitive fatigue subscales. The pattern of slightly lower
correlations for emotional and cognitive fatigue are
appropriate since these concepts likely include an individ-
ual’s response to fatigue; they also reflect the original val-
idation patterns seen during UK development [5].
The similar performance of the original and potential
revised wording for the Spanish RAID coping item
shows that more than one expression may capture the
concept of coping and produce similar results (original
version was therefore retained). There is no consensus
on the common core concepts to be measured in a
coping scale, and a review of 100 coping PROMs identi-
fied >400 coping strategies that could be inquired about
[28]. These specific behavioural, emotional and cognitive
coping strategies may relate to the concept of self-man-
agement highlighted as an important element to be cap-
tured in RA, but for which there is yet no specific PROM
[29]. In contrast, both the BRAF-MDQ and RAID coping
items are simple ratings of the patient’s perspective of
their current overall coping success, rather than asking
about strategies, and might be tapping into the broad
construct of flexible coping seen in RA [30].
In contrast, the issue for the original BRAF-NRS coping
item was operational, relating to the direction of scoring.
TABLE 1 Demographic data overall (n= 1276) and by country
Characteristic
France
(n=206)
Germany
n=216)
The Netherlands
(n=317)
Spain
(n=157)
Sweden
(n=170)
UK
(n=210)
Total
(n=1276)
Female, n (%) 176 (85) 60 (70) 194 (61) 138 (88) 130 (77) 165 (79) 954 (76)
Age, <40 years, n (%) 28 (14) 14 (7) 14 (5) 26 (17) 13 (8) 29 (14) 124 (10)
Age, >60 years, n (%) 88 (43) 109 (51) 192 (62) 42 (27) 108 (65) 91 (44) 630 (50)
Disease duration, 45 years,
n (%)
43 (22) 59 (28) 65 (21) 30 (19) 36 (22) 80 (42) 313 (26)
Biologics, n (%) 95 (46) 65 (30) 105 (33) 66 (42) 108 (64) 33 (16) 472 (37)
BRAF-MDQ total (070) 27.5 (16.6) 22.0 (14.4) 22.0 (14.0) 26.1 (16.7) 27.1 (16.0) 34.2 (17.3) 26.0 (16.2)
Physical (022) 11.7 (5.7) 10.4 (5.5) 11.4 (5.6) 11.3 (6.2) 12.5 (5.7) 14.0 (5.6) 11.8 (5.8)
Living (021) 6.6 (5.7) 5.8 (5.1) 5.3 (4.7) 6.6 (5.4) 6.6 (5.2) 8.7 (6.0) 6.5 (5.4)
Cognitive (015) 4.4 (3.9) 3.5 (3.2) 3.1 (3.2) 4.7 (4.1) 4.7 (3.9) 6.2 (4.4) 4.3 (3.9)
Emotional (012) 4.6 (3.7) 2.4 (2.6) 2.2 (2.5) 3.6 (3.0) 3.5 (3.2) 5.0 (3.4) 3.4 (3.2)
BRAF-NRS
Severity (010) 4.7 (2.4) 4.1 (2.5) 4.6 (2.3) 4.9 (2.8) 5.2 (2.5) 5.9 (2.7) 4.8 (2.6)
Effect (010) 4.4 (2.5) 3.8 (2.5) 4.3 (2.4) 4.8 (2.9) 4.9 (2.6) 5.8 (2.9) 4.6 (2.7)
Coping (original) (010)a 6.0 (2.4) 5.8 (2.7) 6.1 (2.4) 5.7 (2.8) 5.8 (2.5) 6.0 (2.6) 6.0 (2.6)
Coping V2 (revised) (010) 3.8 (2.5) 3.4 (2.4) 3.6 (2.5) 4.2 (2.9) 4.1 (2.5) 5.2 (2.9) 4.0 (2.7)
RAID (010) 3.8 (2.2) 3.7 (2.3) 3.7 (2.0) 4.4 (2.4) 4.5 (2.2) 5.2 (2.5) 4.2 (2.3)
HAQ (03) 0.8 (0.6) 0.9 (0.7) 1.0 (0.7) 1.1 (0.7) 1.1 (0.6) 1.3 (0.8) 1.0 (0.7)
Patient global (010) 4.3 (2.4) 3.9 (2.5) 4.1 (2.3) 4.6 (2.5) 5.0 (2.4) 4.8 (2.6) 4.4 (2.4)
SF-36
Physical function (0100)a 59.0 (26.5) 61.6 (28.9) 57.3 (25.5) 52.1 (26.7) 50.4 (24.2) 37.8 (29.5) 53.5 (28.0)
Physical role (0100)a 37.4 (42.4) 46.0 (42.1) 41.0 (42.3) 38.9 (42.5) 36.7 (40.2) 23.0 (35.5) 37.6 (41.6)
Emotion role (0100)a 53.6 (42.3) 59.9 (45.3) 66.8 (42.2) 54.7 (45.7) 56.7 (44.0) 44.7 (44.1) 57.1 (44.3)
Social role (0100)a 59.9 (21.6) 63.1 (23.4) 65.0 (19.4) 56.4 (24.2) 58.4 (23.7) 48.2 (24.9) 59.2 (23.3)
Pain (0100)a 53.8 (23.4) 52.2 (24.1) 55.1 (20.6) 47.2 (22.9) 44.7 (21.0) 40.4 (25.2) 49.6 (23.4)
Mental health (0100)a 63.0 (18.7) 63.2 (20.8) 72.9 (17.2) 58.9 (20.3) 68.0 (22.3) 60.7 (20.5) 65.3 (20.3)
Vitality (0100)a 51.5 (20.2) 46.9 (22.2) 54.2 (19.4) 44.4 (21.1) 44.7 (24.9) 35.5 (19.9) 47.0 (22.0)
General health (0100)a 46.4 (20.09) 50.3 (20.5) 49.6 (19.0) 40.4 (18.7) 45.4 (22.8) 39.4 (21.7) 45.9 (20.9)
Values presented as mean (S.D.) unless otherwise stated. aLow score = worse health. BRAF-MDQ: British Rheumatoid Arthritis
Fatigue  Multidimensional Questionnaire; BRAF-NRS: British Rheumatoid Arthritis Fatigue  Numerical Rating Scale; RAID:
RA Impact of Disease; SF: Short-form Health Survey (n = 36).
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This direction was formulated in research with patients
who felt that using 0 for not coping and 10 for coping
well made better sense than the traditional direction [4],
although the majority of fatigue PROMs used in rheuma-
tology are scored in the opposite direction [26]. In the
cognitive interviewing study that preceded the present
report, it was Dutch patients who queried this [12], but
in the present study it was Spanish patients who scored
the original BRAF-NRS coping item in the opposite direc-
tion, generating inappropriately negative correlations
(Table 6). In contrast, for the revised BRAF-NRS V2
coping item (0 = coping well), these correlations were in
the appropriate direction for all countries, including
Spain. It is possible that the common use of the double
negative in Spain [31] may be related to their interpretation
of the original 0 for not coping. This illustrates the care
required to ensure equivalence of questionnaires across
countries.
The construct validity for the original BRAF-NRS coping
item is acceptable, but that for the revised BRAF-NRS V2
coping item is improved. The correlation between the ori-
ginal and revised coping items is weak (r= 0.342),
TABLE 2 Percentage of variation in the items accounted for by each factor
Factor
Number of
items
France
(n=206)
Germany
(n=216)
The Netherlands
(n=317)
Spain
(n=157)
Sweden
(n=170)
UK
(n=210)
Total
(n=1276)
BRAF-MDQ
Physical 4 66.1 69.0 70.4 73.1 73.5 72.5 70.5
Living 7 67.0 73.8 68.9 74.8 69.0 73.5 71.1
Cognitive 5 74.1 75.2 76.2 84.4 78.6 84.8 80.0
Emotional 4 74.7 70.1 72.4 73.3 75.9 75.6 75.0
RAID 7 71.7 79.7 74.2 78.0 74.7 76.0 75.6
BRAF-MDQ: British Rheumatoid Arthritis Fatigue  Multidimensional Questionnaire; RAID: RA Impact of Disease.
TABLE 3 Internal consistency of BRAF-MDQ (Cronbach’s a, overall and by country)
Factor
France
(n=206)
Germany
(n=216)
The Netherlands
(n=317)
Spain
(n=157)
Sweden
(n=170)
UK
(n=210)
Total
(n=1276)
BRAF-MDQ total 0.938 0.934 0.932 0.943 0.947 0.954 0.944
Physical 0.750 0.752 0.763 0.782 0.791 0.785 0.770
Living 0.918 0.941 0.924 0.943 0.923 0.940 0.932
Cognitive 0.912 0.916 0.920 0.953 0.931 0.955 0.937
Emotional 0.885 0.852 0.873 0.878 0.893 0.892 0.888
RAID 0.932 0.955 0.938 0.951 0.941 0.945 0.947
BRAF-MDQ: British Rheumatoid Arthritis Fatigue  Multidimensional Questionnaire; RAID: RA Impact of Disease.
TABLE 4 Construct validity of fatigue impact, severity and effect with other fatigue items (correlation coefficient)
Factor
BRAF-MDQ
physical
BRAF-MDQ
living
BRAF-MDQ
cognitive
BRAF-MDQ
emotion
BRAF-NRS
severity
BRAF-NRS
effect
RAID
fatigue
SF-36a
vitality
BRAF-MDQ
Physical 0.858 0.767
Living 0.779 0.733 0.723
Cognitive 0.652 0.707 0.623 0.632
Emotional 0.676 0.758 0.788 0.648 0.646
Total 0.900 0.925 0.845 0.869 0.850 0.854 0.822 0.790
BRAF-NRS
Severity 0.903 0.745 0.633 0.659 0.892 0.732
Effect 0.866 0.771 0.646 0.696 0.915 0.857 0.735
aLow score = worse health. BRAF-MDQ: British Rheumatoid Arthritis Fatigue  Multidimensional Questionnaire; BRAF-NRS:
British Rheumatoid Arthritis Fatigue  Numerical Rating Scale; SF: Short-form Health Survey (n = 36).
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suggesting that different patients are interpreting the ori-
ginal version in different directions. As it is not known
which patients these are, investigators using the original
BRAF-NRS coping item in ongoing studies should not be
tempted to reverse those scores, as they are not mirror
images of each other. Investigators should continue to use
the original version for studies currently under way, as its
performance is acceptable.
TABLE 6 Construct validity for the revised BRAF-NRS V2 coping item (correlation coefficient)
Factor
Original BRAF-
NRSa coping
(10 =good)
(n=1119)
Revised BRAF-
NRS V2 coping
(10 =bad)
(n=1119)
Original BRAF-
NRSa coping
(10=good) (Spain,
n=157)
Revised BRAF-NRS
V2 coping (10 =bad)
(Spain, n=157)
With other fatigue items
BRAF-NRS coping originala 0.348 0.082
BRAF-NRS V2
Severity 0.137 0.545 0.445 0.390
Effect 0.154 0.562 0.438 0.366
BRAF-MDQ
Total score 0.389 0.714 0.290 0.744
Physical 0.153 0.525 0.478 0.350
Living 0.166 0.464 0.348 0.214
Cognitive 0.143 0.380 0.242 0.296
Emotional 0.149 0.404 0.289 0.287
RAID question 7, coping 0.175 0.536 0.369 0.291
SF-36 vitality subscalea 0.172 0.412 0.311 0.258
With related concepts
RAID 0.135 0.558 0.396 0.344
HAQ 0.135 0.391 0.304 0.163
SF-36
Physical functiona 0.140 0.380 0.314 0.136
Physical rolea 0.184 0.401 0.252 0.209
Emotional rolea 0.142 0.334 0.085 0.186
Social rolea 0.178 0.419 0.202 0.325
Paina 0.126 0.391 0.315 0.265
Mental healtha 0.171 0.355 0.104 0.270
General healtha 0.144 0.382 0.135 0.153
aHigh score = better health. BRAF-MDQ: British Rheumatoid Arthritis Fatigue  Multidimensional Questionnaire; BRAF-NRS:
British Rheumatoid Arthritis Fatigue  Numerical Rating Scale; RAID: RA Impact of Disease; SF: Short-form Health Survey
(N = 36).
TABLE 5 Construct validity of disease impact, fatigue impact, severity and effect with related concepts (correlation
coefficient)
Factor RAID HAQ
SF-36a
physical
function
SF-36a
physical
role
SF-36a
emotional
role
SF-36a
social
role
SF-36a
pain
SF-36a
mental
health
SF-36a
general
health
RAID 0.639 0.616 0.641 0.497 0.680 0.783 0.574 0.697
BRAFMDQ
Total 0.786 0.592 0.603 0.677 0.580 0.760 0.657 0.630 0.604
Physical 0.781 0.558 0.613 0.465 0.664 0.634 0.515 0.567
Living 0.730 0.622 0.678 0.547 0.736 0.639 0.569 0.571
Cognitive 0.592 0.427 0.521 0.520 0.620 0.496 0.577 0.476
Emotional 0.640 0.456 0.554 0.569 0.671 0.527 0.646 0.508
BRAF-NRS
Severity 0.815 0.522 0.576 0.457 0.653 0.629 0.503 0.549
Effect 0.821 0.569 0.610 0.501 0.710 0.650 0.564 0.562
aLow score = worse health. BRAF-MDQ: British Rheumatoid Arthritis Fatigue  Multidimensional Questionnaire; BRAF-NRS:
British Rheumatoid Arthritis Fatigue  Numerical Rating Scale; RAID: RA Impact of Disease; SF: Short-form Health Survey
(n = 36).
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A possible limitation of this study might be that the
health status of the UK patient sample was slightly
poorer than the other countries (HAQ, SF-36). This might
have occurred through the approach to patients in the UK,
which was largely at their clinic appointment and thus,
when patients are stable, they only have routine check-
ups every 2 years. In the meantime they have direct
access to rapid appointments via a nurse helpline if they
have a flare [32], meaning patients attending clinics are
generally seeking help for their RA disease control. The
UK sample also comprised fewer patients on biologic
drugs than the other European countries (16% vs
3064%), and lower UK biologic prescribing rates have
been reported previously [33]. Nonetheless, analysis
shows that the BRAFs and RAID performed similarly
across the countries, thus demonstrating effective meas-
urement at a range of different levels of health. The
strength of this study is that it was preceded by system-
atic cognitive interviewing [12] and conducted in a large
group of patients (n= 1276) with a sufficient number from
each of the six countries to allow robust conclusions per
country regarding questionnaire performance. There are
examples in RA studies where PROMs have not been sub-
jected to such detailed post-translation analysis, making it
difficult to interpret the research findings, which may have
significant clinical implications [34]. Validation of the
BRAFs and RAID in other countries and cultures has yet
to be undertaken.
This study demonstrates the potential usefulness of the
BRAFs and RAID across European countries to measure
and compare RA fatigue and impact. Further, it indicates
that fatigue has a common four-factor structure across
countries, paving the way for interventions targeting dif-
ferent issues (e.g. lifestyle, cognition, emotion) that could
be tested internationally. Three further psychometric
steps could build upon the work presented here. First,
clarification of individual item performance by country
could be explored, perhaps using Item Response Theory
[35]. This would identify any potential for improving scale
sensitivity by differential scoring within countries. Second,
international longitudinal studies could measure reliability
and sensitivity to change. This is particularly important to
explore changes in the four fatigue dimensions, which
might respond differentially depending on the nature of
the intervention (e.g. physical and living with fatigue re-
sponding to pharmacological interventions and cognitive
and emotional fatigue responding to cognitive interven-
tions). Third, it would be useful to examine the BRAFs
and RAID for evaluating fatigue, impact and coping
beyond these western cultures.
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